S&P 500   4,507.84 (+0.48%)
DOW   35,385.49 (+0.36%)
QQQ   374.32 (+0.45%)
AAPL   148.27 (+1.17%)
MSFT   308.39 (+0.36%)
FB   338.44 (+0.92%)
GOOGL   2,856.59 (+0.04%)
TSLA   868.93 (-0.14%)
AMZN   3,434.66 (-0.35%)
NVDA   221.27 (-0.43%)
BABA   172.46 (+3.38%)
NIO   39.91 (+0.76%)
CGC   13.42 (+1.67%)
GE   104.26 (+0.13%)
AMD   115.29 (-0.98%)
MU   66.98 (-0.42%)
T   25.41 (+0.32%)
F   15.55 (-0.06%)
ACB   6.97 (+0.72%)
DIS   170.45 (-0.40%)
PFE   41.90 (+1.40%)
BA   216.01 (-0.45%)
AMC   43.31 (+0.65%)
S&P 500   4,507.84 (+0.48%)
DOW   35,385.49 (+0.36%)
QQQ   374.32 (+0.45%)
AAPL   148.27 (+1.17%)
MSFT   308.39 (+0.36%)
FB   338.44 (+0.92%)
GOOGL   2,856.59 (+0.04%)
TSLA   868.93 (-0.14%)
AMZN   3,434.66 (-0.35%)
NVDA   221.27 (-0.43%)
BABA   172.46 (+3.38%)
NIO   39.91 (+0.76%)
CGC   13.42 (+1.67%)
GE   104.26 (+0.13%)
AMD   115.29 (-0.98%)
MU   66.98 (-0.42%)
T   25.41 (+0.32%)
F   15.55 (-0.06%)
ACB   6.97 (+0.72%)
DIS   170.45 (-0.40%)
PFE   41.90 (+1.40%)
BA   216.01 (-0.45%)
AMC   43.31 (+0.65%)
S&P 500   4,507.84 (+0.48%)
DOW   35,385.49 (+0.36%)
QQQ   374.32 (+0.45%)
AAPL   148.27 (+1.17%)
MSFT   308.39 (+0.36%)
FB   338.44 (+0.92%)
GOOGL   2,856.59 (+0.04%)
TSLA   868.93 (-0.14%)
AMZN   3,434.66 (-0.35%)
NVDA   221.27 (-0.43%)
BABA   172.46 (+3.38%)
NIO   39.91 (+0.76%)
CGC   13.42 (+1.67%)
GE   104.26 (+0.13%)
AMD   115.29 (-0.98%)
MU   66.98 (-0.42%)
T   25.41 (+0.32%)
F   15.55 (-0.06%)
ACB   6.97 (+0.72%)
DIS   170.45 (-0.40%)
PFE   41.90 (+1.40%)
BA   216.01 (-0.45%)
AMC   43.31 (+0.65%)
S&P 500   4,507.84 (+0.48%)
DOW   35,385.49 (+0.36%)
QQQ   374.32 (+0.45%)
AAPL   148.27 (+1.17%)
MSFT   308.39 (+0.36%)
FB   338.44 (+0.92%)
GOOGL   2,856.59 (+0.04%)
TSLA   868.93 (-0.14%)
AMZN   3,434.66 (-0.35%)
NVDA   221.27 (-0.43%)
BABA   172.46 (+3.38%)
NIO   39.91 (+0.76%)
CGC   13.42 (+1.67%)
GE   104.26 (+0.13%)
AMD   115.29 (-0.98%)
MU   66.98 (-0.42%)
T   25.41 (+0.32%)
F   15.55 (-0.06%)
ACB   6.97 (+0.72%)
DIS   170.45 (-0.40%)
PFE   41.90 (+1.40%)
BA   216.01 (-0.45%)
AMC   43.31 (+0.65%)

Grifols Stock Forecast, Price & News

$13.74
-0.05 (-0.36 %)
(As of 10/19/2021 10:20 AM ET)
Add
Compare
Today's Range
$13.70
$13.81
50-Day Range
$13.67
$15.82
52-Week Range
$13.57
$20.49
Volume5,399 shs
Average Volume769,069 shs
Market Capitalization$9.32 billion
P/E Ratio12.05
Dividend Yield5.06%
Beta0.56
30 days | 90 days | 365 days | Advanced Chart
Receive GRFS News and Ratings via Email

Sign-up to receive the latest news and ratings for Grifols and its competitors with MarketBeat's FREE daily newsletter.


Grifols logo

About Grifols

Grifols SA engages in the production of plasma derivatives. It operates through the following segments: Bioscience, Hospital, Diagnostic, Bio Supplies, and Others. The Bioscience Segment includes all activities related with products deriving from human plasma for therapeutic use. The Hospital Segment comprises of all non-biological pharmaceutical products and medical supplies manufactured by group companies earmarked for hospital pharmacy. The Diagnostic Segment deals with the marketing of diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment consists of all transactions related to biological products for non-therapeutic use. The Others segment focuses on the rendering of manufacturing services to third party companies. The company was founded by José Antonio Grifols Roig on November 18, 1940 and is headquartered in Barcelona, Spain.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:GRFS
Employees
2,020
Year Founded
1909

Sales & Book Value

Annual Sales
$6.10 billion
Cash Flow
$1.72 per share
Book Value
$11.16 per share

Profitability

Net Income
$706.57 million

Debt

Price-To-Earnings

Miscellaneous

Market Cap
$9.32 billion
Next Earnings Date
11/4/2021 (Estimated)
Optionable
Optionable

Social Links


MarketRank

Overall MarketRank

2.19 out of 5 stars

Medical Sector

373rd out of 1,361 stocks

Pharmaceutical Preparations Industry

168th out of 668 stocks

Analyst Opinion: 0.0Community Rank: 3.9Dividend Strength: 3.3Insider Behavior: 0.0Valuation: 3.8 5 -4 -3 -2 -1 -












Grifols (NASDAQ:GRFS) Frequently Asked Questions

Is Grifols a buy right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Grifols in the last twelve months. There are currently 1 sell rating, 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Grifols stock.
View analyst ratings for Grifols
or view top-rated stocks.

What stocks does MarketBeat like better than Grifols?

Wall Street analysts have given Grifols a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Grifols wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Grifols' next earnings date?

Grifols is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Grifols
.

How were Grifols' earnings last quarter?

Grifols, S.A. (NASDAQ:GRFS) announced its earnings results on Thursday, July, 29th. The biotechnology company reported $0.35 EPS for the quarter, beating analysts' consensus estimates of $0.27 by $0.08. The biotechnology company earned $1.63 billion during the quarter. Grifols had a trailing twelve-month return on equity of 9.98% and a net margin of 12.71%.
View Grifols' earnings history
.

How has Grifols' stock been impacted by Coronavirus (COVID-19)?

Grifols' stock was trading at $20.36 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, GRFS shares have decreased by 32.4% and is now trading at $13.77.
View which stocks have been most impacted by COVID-19
.

How often does Grifols pay dividends? What is the dividend yield for Grifols?

Grifols declared a semi-annual dividend on Wednesday, May 26th. Shareholders of record on Friday, June 4th will be given a dividend of $0.4385 per share on Monday, June 14th. This represents a dividend yield of 2.6%. The ex-dividend date is Thursday, June 3rd. This is a positive change from Grifols's previous semi-annual dividend of $0.14.
View Grifols' dividend history
.

Is Grifols a good dividend stock?

Grifols pays an annual dividend of $0.72 per share and currently has a dividend yield of 5.06%. GRFS has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. Grifols does not yet have a strong track record of dividend growth. The dividend payout ratio of Grifols is 58.54%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Grifols will have a dividend payout ratio of 48.32% next year. This indicates that Grifols will be able to sustain or increase its dividend.
View Grifols' dividend history.

When did Grifols' stock split? How did Grifols' stock split work?

Shares of Grifols split on the morning of Monday, January 4th 2016. The 2-1 split was announced on Thursday, December 3rd 2015. The newly issued shares were payable to shareholders after the market closes on Thursday, December 31st 2015. An investor that had 100 shares of Grifols stock prior to the split would have 200 shares after the split.

Who are Grifols' key executives?

Grifols' management team includes the following people:
  • Raimon Grifols Roura, Joint Chief Executive Officer & Executive Director
  • Victor Grifols Deu, Joint Chief Executive Officer & Executive Director
  • Alfredo Arroyo Guerra, Chief Financial Officer & Vice President
  • Xavier Sueiras Gil, Chief Information Technology Officer
  • Antonio Martínez Martínez, President-Diagnostic Scientific, R&D

What is Raimon Grifols and Victor Grifols Deu's approval rating as Grifols' CEO?

205 employees have rated Grifols CEO Raimon Grifols and Victor Grifols Deu on Glassdoor.com. Raimon Grifols and Victor Grifols Deu has an approval rating of 68% among Grifols' employees.

What other stocks do shareholders of Grifols own?

What is Grifols' stock symbol?

Grifols trades on the NASDAQ under the ticker symbol "GRFS."

Who are Grifols' major shareholders?

Grifols' stock is owned by a variety of institutional and retail investors. Top institutional investors include Veriti Management LLC (0.00%) and AdvisorNet Financial Inc (0.00%).

Which institutional investors are buying Grifols stock?

GRFS stock was purchased by a variety of institutional investors in the last quarter, including Veriti Management LLC, and AdvisorNet Financial Inc.

How do I buy shares of Grifols?

Shares of GRFS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Grifols' stock price today?

One share of GRFS stock can currently be purchased for approximately $13.77.

How much money does Grifols make?

Grifols has a market capitalization of $9.34 billion and generates $6.10 billion in revenue each year. The biotechnology company earns $706.57 million in net income (profit) each year or $1.23 on an earnings per share basis.

How many employees does Grifols have?

Grifols employs 2,020 workers across the globe.

Does Grifols have any subsidiaries?

The following companies are subsidiares of Grifols: Aigües Minerals de Vilajuiga S.A., Araclon Biotech, Araclon Biotech S.L., Asociación I+D Progenika, Biomat S.A., Biomat USA Inc., Biotest Pharmaceutical Corporation, Biotest US Corporation, Chiquito Acquisition Corp., Diagnostic Grifols S.A., Goetech LLC (D/B/A Medkeeper), Gri-Cel S.A. , Grifols (H.K.) Limited, Grifols (Thailand) Ltd, Grifols Argentina S.A., Grifols Asia Pacific Pte Ltd, Grifols Australia Pty Ltd., Grifols Biologicals LLC., Grifols Brasil Lda., Grifols Canada Ltd., Grifols Chile S.A., Grifols Colombia Ltda, Grifols Deutschland GmbH, Grifols Diagnostics Equipment Taiwan Limited, Grifols Diagnostics Solutions Inc, Grifols Engineering S.A., Grifols France S.A.R.L., Grifols India Healthcare Private Ltd, Grifols Innovation and New Technologies Limited, Grifols International S.A., Grifols Italia S.p.A, Grifols Japan K.K., Grifols Malaysia Sdn Bhd, Grifols Movaco S.A., Grifols México S.A. de C.V., Grifols Nordic AB, Grifols Pharmaceutical Technology (Shanghai) Co. Ltd., Grifols Polska Sp.z.o.o., Grifols Portugal Productos Farmacéuticos e Hospitalares Lda., Grifols Shared Services North America Inc., Grifols Switzerland AG, Grifols Therapeutics LLC., Grifols UK Ltd., Grifols USA LLC., Grifols Viajes S.A., Grifols Worldwide Operations Limited, Grifols Worldwide Operations Spain S.A., Grifols Worldwide Operations USA Inc., Grifols s.r.o., Gripdan Invest S.L, Haema AG, Instituto Grifols S.A., Interstate Blood Bank Inc., Kiro Grifols S.L, Kiro Robotics, Laboratorios Grifols S.A., Logística Grifols S.A. de C.V., Medion Diagnostics GmbH, Medion Grifols Diagnostic AG, PBS Acquisition Corp., Progenika Biopharma, Progenika Biopharma S.A., Squadron Reinsurance Designated Activity Company, Talecris Biotherapeutics, Talecris Plasma Resources Inc., and VCN Bioscience S.L..

When was Grifols founded?

Grifols was founded in 1909.

What is Grifols' official website?

The official website for Grifols is www.grifols.com.

Where are Grifols' headquarters?

How can I contact Grifols?

Grifols' mailing address is 152 PARC DE NEGOCIS CAN SANT JOAN SANT CUGAT DEL VALL¿S, BARCELONA U3, 08174. The biotechnology company can be reached via phone at (493) 571-2200 or via email at [email protected].


This page was last updated on 10/19/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.